HepaCure

血浆生物净化柱

Report date: 2025/02/27 20:00:09

Base Information

Drug NameHepaCure
Drug Alias NameHepaCure生物人工肝
ClassificationCell and gene therapy > Cell therapy > Somatic cell > Hepatocyte-like cell therapyCell and gene therapy > Cell therapy > Source of cells > Fibroblasts-derived
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsHepatitisAcute-On-Chronic Liver FailureLiver Failure, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Hexaell Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Hexaell Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitisAcute-On-Chronic Liver FailureLiver Failure, Acute +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A